

**SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission**

**Authors**

Arnaud Fontanet, MD, DrPH<sup>1,2</sup>

Rebecca Grant<sup>1</sup>

Laura Tondeur, MSc<sup>1</sup>

Yoann Madec, PhD<sup>1</sup>

Ludivine Grzelak<sup>3,4,5</sup>

Isabelle Cailleau, MSc<sup>6</sup>

Marie-Noëlle Ungeheuer, MD, PhD<sup>7</sup>

Charlotte Renaudat, MD<sup>7</sup>

Sandrine Fernandes Pellerin, PhD<sup>8</sup>

Lucie Kuhmel, MD<sup>9</sup>

Isabelle Staropoli<sup>3</sup>

François Anna<sup>10</sup>

Pierre Chameau<sup>10,11</sup>

Caroline Demeret<sup>12</sup>

Timothée Bruel, PhD<sup>3</sup>

Olivier Schwartz, PhD<sup>3,4,5,13</sup>

Bruno Hoen, MD, PhD<sup>1,6</sup>

**Affiliations**

<sup>1</sup> Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France

<sup>2</sup> PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France

<sup>3</sup> Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France,

<sup>4</sup> UMR 3569, Centre National de la Recherche Scientifique (CNRS), France

<sup>5</sup> Université de Paris, Sorbonne Paris Cité, Paris, France

<sup>6</sup> Direction de la recherche médicale, Institut Pasteur, Paris, France

<sup>7</sup> ICAREB platform (Clinical Investigation & Access to Research Bioresources) of the Center for translational Science, Institut Pasteur, Paris, France

<sup>8</sup> Center for Translational Sciences, Institut Pasteur, Paris, France

<sup>9</sup> Medical Center of the Institut Pasteur, Institut Pasteur, Paris, France

<sup>10</sup> Laboratoire Commun Pasteur/TheraVectys, Institut Pasteur, Paris, France

<sup>11</sup> Unité de Virologie Moléculaire et Vaccinologie, Institut Pasteur, Paris, France

<sup>12</sup> Molecular Genetics of RNA Viruses, Institut Pasteur, Paris, France

<sup>13</sup> Vaccine Research Institute, Creteil, France

Corresponding author:

Arnaud Fontanet

Emerging Diseases Epidemiology Unit

Institut Pasteur

25 rue du Docteur Roux, Paris 75015, France

Email: fontanet@pasteur.fr

Telephone: + 33 (0)1 45 68 80 00

**SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission**

**Abstract**

**Background:** The extent of SARS-CoV-2 transmission among pupils in primary schools and their families is unknown.

**Methods:** Between 28-30 April 2020, a retrospective cohort study was conducted among pupils, their parents and relatives, and staff of primary schools exposed to SARS-CoV-2 in February and March 2020 in a city north of Paris, France. Participants completed a questionnaire that covered sociodemographic information and history of recent symptoms. A blood sample was tested for the presence of anti-SARS-CoV-2 antibodies using a flow-cytometry-based assay.

**Results:** The infection attack rate (IAR) was 45/510 (8.8%), 3/42 (7.1%), 1/28 (3.6%), 76/641 (11.9%) and 14/119 (11.8%) among primary school pupils, teachers, non-teaching staff, parents, and relatives, respectively ( $P = 0.29$ ). Prior to school closure on February 14, three SARS-CoV-2 infected pupils attended three separate schools with no secondary case in the following 14 days among pupils, teachers and non-teaching staff of the same schools. Familial clustering of cases was evidenced by the high proportion of antibodies among parents and relatives of infected pupils (36/59 = 61.0% and 4/9 = 44.4%, respectively). In children, disease manifestations were mild, and 24/58 (41.4%) of infected children were asymptomatic.

**Interpretation:** In young children, SARS-CoV-2 infection was largely a- or pauci-symptomatic and there was no evidence of onwards transmission from children in the school setting.

## Introduction

As the coronavirus (COVID-19) pandemic continues to evolve, the extent of SARS-CoV-2 infection in children has not been well estimated and the role children may play in virus transmission remains unclear. During the first epidemic wave, many countries included school closures among the measures implemented to limit viral transmission, based on the prior knowledge of the impact of school closures on influenza transmission<sup>1,2</sup>. As many schools are now reopening, it is critical to evaluate the risk of viral circulation among pupils and their teachers in schools<sup>3</sup>.

Initial epidemiological data from China indicated that children were significantly less affected than adults, whether considering the total number of clinical cases, disease severity or fatal outcomes<sup>4</sup>. Similar findings were also reported in other countries<sup>5-7</sup>. It is now understood that children, when infected, present with mild and asymptomatic forms of the disease more often than adults<sup>8-10</sup>, with severe and fatal outcomes remaining rare in children<sup>11-12</sup>.

Younger children are generally thought to be less susceptible to infection as compared to adults<sup>13-16</sup>, and, when infected, are usually contaminated by a household member<sup>17</sup>. Some studies have nevertheless documented secondary attack rates in families as high in children as in adults<sup>18</sup>. Children, when found infected, may carry the virus in their throats for 9-11 days<sup>17</sup> and for up to one month in stools<sup>19</sup>. Viral loads have been found to be similar between infected children and adults<sup>20-21</sup>, which would suggest that children may be as infectious as adults. It is therefore unclear why children would be less susceptible, and less infectious, as compared to adults<sup>22</sup>. Seroepidemiological studies are thus needed to determine the extent of infection in children and to decipher the role they may play in transmission

To our knowledge, the number of SARS-CoV-2 secondary transmissions in school setting documented in scientific literature is limited, with very few or no secondary case out of several investigations in Australia<sup>23</sup>, Ireland<sup>24</sup>, and France<sup>25</sup>, with the exception of one important cluster in a high school north of Paris in February 2020<sup>26</sup>.

It is all the more important to understand the extent of infection in children and the role they may play in transmission given the likely negative effects of school closures on educational achievement and economic outcomes<sup>3</sup>. To investigate the extent of infection in younger children, a follow-up seroepidemiologic investigation to that in the high school was conducted across primary schools in the same city north of Paris, France. Here, we present the results of the follow up investigation in primary schools.

## **Methods**

### *Study setting*

An initial retrospective epidemiological investigation was conducted in the Crépy-en-Valois city (15,000 inhabitants) north of Paris, France after the diagnosis of the first case of COVID-19 on 24 February 2020. This investigation identified an epidemic around a local high school with two teachers having symptoms consistent with COVID-19 as early as on 2 February 2020. Since there was no known circulation of SARS-CoV-2 at that time in the region, no public health or social measures intended to limit the viral transmission had been implemented and no active SARS-CoV-2 testing had been conducted. A preliminary rapid investigation among symptomatic adults and pupils at the high school on 5-6 March 2020 revealed that 11/66 (16.7%) adults and 2/24 (8.3%) pupils had acute infection, as determined by a positive RT-PCR test result. As a follow-up to this rapid investigation, the decision was made to further examine by serological testing the extent of infection among pupils, their parents and relatives, teaching staff and non-teaching staff of 1) the high school where the two teachers worked and 2) the primary schools in the same city. The high school investigation has previously been reported<sup>26</sup>. Here, we describe the follow-up seroepidemiologic investigation across six primary schools from the same city, with children aged 6 to 11 years.

### *Study design*

A retrospective cohort study was conducted by inviting all pupils, teachers and non-teaching staff (administrative, cleaners, catering) from each of the six primary schools who were registered at the school from the beginning of the epidemic (estimated around 13 January 2020) up to the time of the investigation (28-30 April 2020). Since pupils were minor, at least one parent was invited to provide informed consent for their child. They were also invited to participate in the study if they were willing to do so, as well as any of the other children or relatives over the age of 5 years of the household.

Following informed consent, participants (with the help of their parents in the case of pupils) completed a questionnaire that covered sociodemographic information, underlying medical conditions, history of

recent symptoms, and history of COVID-19 diagnosis prior to this investigation. A 5-mL blood sample was taken from all participants.

#### *Laboratory analyses*

Samples were conveyed to and stored in the Clinical Investigation and Access to BioResources (ICAReB) biobank platform of Institut Pasteur (Paris, France), which collects and manages human bioresources for scientific purposes, following ISO 9001 and NF S 96-900 quality standards (BRIF code n°BB-0033-00062). Serological testing was conducted using the S-Flow assay, a flow-cytometry-based serological test developed by the Institut Pasteur. The assay is based on the recognition of the SARS-CoV-2 Spike protein expressed at the surface of 293T cells. In previous studies, the sensitivity of the assay was estimated at 99.4% (95% confidence interval (CI) = 96.6% - 100%) on a panel of 160 RT-PCR confirmed mild forms of COVID-19<sup>27</sup>, while its specificity was found to be 100% (one-sided 97.5% CI = 97.4% - 100%) on a panel of 140 pre-epidemic sera<sup>28</sup>.

#### *Case definitions*

Any participant with a positive serology at the time of blood sampling was considered as having had SARS-CoV-2 infection. Each infection was categorized as symptomatic if any recent symptoms were reported by the participant up until 7 days prior to the date of sample collection to allow sufficient time for seroconversion<sup>29,30</sup>, or, alternatively, as asymptomatic. Symptoms were further categorized as major (fever, dry cough, dyspnea, anosmia and ageusia) or minor (sore throat, rhinitis, muscle pain, diarrhea, headache, asthenia, vomiting, nausea, chest pain, abdominal pain).

#### *Statistical analyses*

The IAR was defined as the proportion of all participants with SARS-CoV-2 infection based on antibody detection in the collected blood sample by the end of the first COVID-19 epidemic wave. Participants were further categorized as children if under 18 years of age (pupils, relatives of the pupil living in the same household) and adults if 18 years or older. The analysis was also broken down by school, and by time period (before and after February 14, date of the school closure for two-week

holidays immediately followed by a local lockdown on March 1<sup>st</sup>). The IAR was compared according to participants characteristics using chi-square test and Fisher exact test, where appropriate. All statistical analyses were performed using Stata 15.0 (StataCorp, College Station, TX, USA).

*Ethical considerations*

This study was registered with ClinicalTrials.gov (NCT04325646) and received ethical approval by the Comité de Protection des Personnes Ile de France III. Informed consent was obtained from all participants.



## Results

From 28 to 30 April 2020, 1047 pupils and 51 teachers, from six primary schools, with children aged 6 to 11 years, were invited by email to participate in the investigation. Of these, 541 (51.5%) pupils and 46 (90.2%) teachers accepted to participate in the study. Thirty-one pupils were excluded as they refused phlebotomy, as were four teachers not affiliated with any of the six schools. This resulted in 510 pupils and 42 teachers being analyzed. In addition, 641 parents of pupils, 119 relatives of pupils sharing the same household, and 28 non-teaching staff completed the study population (Figure 1). Table 1 indicates the characteristics of the 1340 participants. Pupils and their parents constituted the majority of the study population (38.1% and 47.8%, respectively).

Most participants were female (57.4%), particularly among teaching (90.5%) and non-teaching (89.3%) staff. The pupils were aged 6-11 years, while the median (IQR) age was 40 (37-44) years for parents, 47.5 (40-51) years for teachers, and 47.5 (32-54) years for non-teaching staff (Table 1).

The overall IAR across study participants was 139/1340 (10.4%). It did not differ by gender, age categories, or type of participants (Table 2). The epidemic curve, based on symptoms experienced by participants with SARS-CoV-2 antibodies, had no specific pattern, and transmission does not appear to have been impacted by the closure of schools for holidays on February 14 (end of week 7) (Figure 2A). There were three instances in three separate schools of high suspicion of SARS-CoV-2 infection in pupils before the closure of the school for holidays (end of week 7), one in week 6, and two in week 7. There were no secondary cases in pupils, teachers and non-teaching staff of the corresponding schools in the 14 days following these initial cases, except for one teacher who had onset of symptoms nine days later, but also had a close contact with a confirmed case outside of the school five days prior to becoming sick. Parents of infected pupils had higher IAR compared to parents of non-infected pupils (61.0% versus 6.9%;  $P < 0.0001$ ), and relatives of infected pupils had higher IAR compared to relatives of non-infected ones (44.4% versus 9.1%;  $P = 0.002$ ) (Table 2 & Figure S1).

Among adults, fever, cough, dyspnea, ageusia, anosmia, muscle pain, sore throat, headache, asthenia, and diarrhea were all associated with positive SARS-CoV-2 antibodies (Table 3). Ageusia and anosmia, reported among 48% of adult participants, had a high positive predictive value for infection: 75.0% and 90.7%, respectively. In children, only asthenia and diarrhea were associated with SARS-CoV-2 antibodies. Only two children with SARS-CoV-2 antibodies experienced anosmia and ageusia, and both were 15 years of age. Among the 139 participants with SARS-CoV-2 antibodies, only two (1.4%, 95% CI = 0.2% - 5.1%), both parents, were hospitalized. There was no death. Across the study period, 9.9% of seropositive adults, and 41.4% of seropositive children, reported no symptoms ( $P < 0.001$ ). Symptoms of respiratory infections – fever, cough, rhinitis- were common among the participants without SARS-CoV-2 antibodies during the study period, with a marked decrease after lockdown was introduced on 1 March 2020 (Figure 2B).

## Discussion

This study in one of the first seroepidemiologic investigation on SARS-CoV-2 in the setting of primary schools. Despite three introductions of the virus into three primary schools, there was no further spread of the virus towards other pupils or teaching and non-teaching staff of the schools. In families of infected pupils, the prevalence of antibodies was very high, suggesting intrafamilial clustering of infections. Finally, children experienced mild forms of disease, many of them being asymptomatic.

We can infer from the reported date of symptom onset among seropositive individuals that viral circulation in the study population presumably began around week 5 (27-31 January 2020). Transmission continued to increase up to week 10 (2-6 March), with no effect of school closure for holidays (14 February). Transmission stabilized and then declined after week 13 (23-27 March). Since there was no reported circulation of SARS-CoV-2 during the month of February in the region until the diagnosis of the first local case on 24 February 2020, adherence to any public health or social measures intended to limit the transmission of the virus was likely low, allowing us to study the natural circulation of the virus in the community.

We could identify three symptomatic SARS-CoV-2 infected pupils in three separate schools during the three weeks preceding closure of the school for holidays and then lockdown. There were no secondary cases in pupils, teachers and non-teaching staff of the corresponding schools in the 14 days following these initial cases. These findings are in line with previous studies from Australia<sup>23</sup>, Ireland<sup>24</sup>, or France<sup>25</sup>. They differ however from the results of the study performed in the high school of the same city, where 38% of pupils, 43% of teaching staff and 59% of non-teaching staff who participated in the investigation had anti-SARS-CoV-2 antibodies<sup>26</sup>. This latter study would suggest that high school aged children have similar susceptibility to SARS-CoV-2 infection as adults, and can transmit SARS-CoV-2 efficiently. The reasons why the observed onwards transmission from children was lower than in adolescents warrant further investigation. Given that viral load among infected children and adults have been found to be similar<sup>20,21</sup>, milder symptoms among children may explain the reduced onward transmission. In families, a different pattern emerged, with high prevalence of antibodies among parents

and relatives of infected pupils (61% and 44%, respectively). Considering the low onward transmission from pupils in schools, the high prevalence figures observed in families more likely resulted from a contamination of children by their parents rather than the opposite, which has already been suggested by others<sup>17</sup>.

In adults, symptoms associated with COVID-19 were fever, cough, shortness of breath, ageusia, anosmia, headache, asthenia, muscle pain, sore throat, and diarrhea, all known features of the disease. Symptoms with highest predictive values for COVID-19 were anosmia and ageusia, as previously reported<sup>31</sup>. Symptoms were less specific in children, with only fatigue and diarrhea being associated with COVID-19. Anosmia and ageusia were rarely seen (1% of children), and only after the age of 15. This study also gave an opportunity to estimate the proportion of asymptomatic forms among infected, showing that they were more common in children than in adults (41.4% vs 9.9%, respectively;  $P < 0.001$ ).

Our results are limited by the short time window for studying the impact of the presence of infected pupils in schools before closure, which happened only two weeks after the first cases of COVID-19 developed in pupils. Still, the absence of well characterized viral spread in the primary school as opposed to what had been observed in the nearby high school at the same time suggests that 6-11 years aged pupils are less contagious than teenager pupils. Another limitation was the incomplete sampling of classes and families, preventing from a full exploration of viral circulation in the schools and households. The clinical findings of our investigation were also limited by the fact that information on symptoms was collected retrospectively, and that other respiratory viruses were circulating concurrently in the study population.

## **Conclusion**

The findings of our investigation are in line with other reports which suggest limited transmission of SARS-CoV-2 in primary schools. These findings suggest that reopening of primary schools can be considered carefully, with continuous monitoring of possible resurgence in infections and strategies to limit transmission such as masks for older children, physical distancing, respiratory etiquette and hand hygiene.

### **Acknowledgements**

We would like to thank the Directorate General for Health for facilitating the initiation of the study, Santé publique France for linking with their investigation team, the Agence Régionale de Santé des Hauts de France, and the Academia of Amiens for their continuous support throughout the realization of the study, especially Ms. Delphine Maskara. We would like to thank the mayor of Crépy-en-Valois, Bruno Fortier and his team, Mrs Sandra Riveros, the local police, and local paramedical staff, Nathalie Bourgeois, Mélissa Mannevy, and Michaël Mannevy, for their help in the implementation of the study. We would like also to thank Nathalie de Parseval, Claire Dugast, Valentine Garaud, Soazic Gardais, Caroline Jannet, Fanny Momboisse, Isabelle Porteret, Hantaniaina Rafanoson, Sandrine Ropars who participated in the organization and the realization of the field investigation. Julian Buchrieser and Rémy Robinot who assisted in the development of serological tests. And finally Nathalie Jolly and Cassandre van Platen, who took care of the regulatory aspects of the study, and Christine Fanaud who informed the participants of their serological status.

### **Role of the funding source**

The study was funded by Institut Pasteur, and several laboratories participating in the study receive funding from the Labex IBEID (ANR-10-LABX-62-IBEID), REACTing and the INCEPTION project (PIA/ANR-16-CONV-0005) for studies focusing on emerging viruses. OS lab is funded by Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR- 10-LABX-77), "TIMTAMDEN" ANR-14-CE14-0029, "CHIKV-Viro- Immuno" ANR-14-CE14-0015-01 and the Gilead HIV cure program. LG is supported by the French Ministry of Higher Education, Research and Innovation.

## References

1. Cauchemez S, Valleron, AJ, Boëlle PY, Ferguson NM. Estimating the impact of school closure on influenza transmission from Sentinel data. *Nature*, 2008;452:750-4
2. Litvinova M, Liu QH, Kulikov ES, Ajelli M Reactive school closure weakens the network of social interactions and reduces the spread of influenza, *PNAS*, 2019;116:13174-13181
3. Esposito S, Principi N. School Closure During the Coronavirus Disease 2019 (COVID-19) Pandemic: An Effective Intervention at the Global Level? *JAMA Pediatr.* 2020. doi:10.1001/jamapediatrics.2020.1892
4. China CDC. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. Feb 2020
5. Docherty AB, Harrison EM, Green CA et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. *Medrxiv* 2020; doi: 10.1101/2020.04.23.20076042
6. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020. *MMWR* 2020;69: 422–426.
7. Riccardo F, Ajelli M, Andrianou X et al. Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic. *Medrxiv* 2020; doi: 10.1101/2020.04.08.20056861.
8. Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. *J Formos Med Assoc* 2020;119:670-673.
9. Dong Y, Mo X, Hu Y et al. Epidemiology of Covid-19 among children in China. *Pediatrics.* 2020 doi: 10.1542/peds.2020-0702.
10. Choi SH , Kim HW, Kang JM et al. Epidemiology and clinical features of coronavirus disease 2019 in children. *Clin Exp Pediatr.* 2020; 63:125–132.
11. Shekerdeman LS, Mahmood NR, Wolfe KK, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatr.* 2020. doi:10.1001/jamapediatrics.2020.1948
12. Verdoni L, Mazza A, Gervasoni A et al. An Outbreak of Severe Kawasaki-like Disease at the Italian Epicentre of the SARS-CoV-2 Epidemic: An Observational Cohort Study. *Lancet* 2020;395: 1771-1778.
13. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med.* 2020; doi: 10.1056/NEJMoa2006100.
14. Viner RM, Mytton OT, Bonel C et al. Susceptibility to and transmission of COVID-19 amongst children and adolescents compared with adults: a systematic review and meta-analysis. *Medrxiv* 2020; doi:10.1101/2020.05.20.20108126
15. Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of COVID-19 outbreak in the municipality of Vo', Italy. *medRxiv.* <https://doi.org/10.1101/2020.04.17.20053157>

16. Stringhini S, Wisniak A, Piumatti G et al., Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet* [https://doi.org/10.1016/S0140-6736\(20\)31304-0](https://doi.org/10.1016/S0140-6736(20)31304-0)
17. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis* 2020; S1473-3099(20)30198-5. doi: 10.1016/S1473-3099(20)30198-5.
18. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* 2020; doi:10.1016/S1473-3099(20)30287-5.
19. Jiehao C, Jing X, Daojiong L et al. A Case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. *Clin Infect Dis* 2020 doi:10.1093/cid/ciaa198
20. Jones TC, Mühlemann B, Veith T et al. An analysis of SARS-CoV-2 viral load by patient age. [https://zoonosen.charite.de/fileadmin/user\\_upload/microsites/m\\_cc05/virologie-ccm/dateien\\_upload/Weitere\\_Dateien/analysis-of-SARS-CoV-2-viral-load-by-patient-age.pdf](https://zoonosen.charite.de/fileadmin/user_upload/microsites/m_cc05/virologie-ccm/dateien_upload/Weitere_Dateien/analysis-of-SARS-CoV-2-viral-load-by-patient-age.pdf)
21. L'Huillier A, Torriani G, Pigny F, Kaiser L, Eckerle I. Shedding of infectious SARS-CoV-2 in symptomatic neonates, children and adolescents. *Medrxiv* 2020 doi: 10.1101/2020.04.27.20076778
22. Patel AB, Verma A. Nasal ACE2 Levels and COVID-19 in Children. *JAMA* 2020. doi:10.1001/jama.2020.8946
23. NCIRS. COVID-19 in schools – the experience in NSW. Sydney: NSW Government, 2020. [http://ncirs.org.au/sites/default/files/2020-04/NCIRS%20NSW%20Schools%20COVID\\_Summary\\_FINAL%20public\\_26%20April%202020.pdf](http://ncirs.org.au/sites/default/files/2020-04/NCIRS%20NSW%20Schools%20COVID_Summary_FINAL%20public_26%20April%202020.pdf)
24. Heavey L, Casey G, Kelly C, Kelly D, McDarby G. No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020. *Euro Surveill*. 2020;25(21):pii=2000903. <https://doi.org/10.2807/1560-7917.ES.2020.25.21.2000903>
25. Danis K, Epaulard O, Bénét T, et al. Cluster of coronavirus disease 2019 (COVID-19) in the French Alps, February 2020. *Clin Infect Dis* 2020
26. Fontanet A, Tondeur L, Madec Y et al. Cluster of COVID-19 in northern France: A retrospective closed cohort study. *Medrxiv* 2020; 2020.04.18.20071134.
27. Fafi-Kremer S, Bruel T, Madec Y et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. *Medrxiv* 2020; 2020.05.19.20101832.
28. Grzelak L, Temmam S, Planchais C, et al. SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors. *Medrxiv* 2020; 2020.04.21.20068858.
29. Wölfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020. <https://doi.org/10.1038/s41586-020-2196-x>.
30. Zhao J, Yuan Q, Wang H et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis* 2020; doi: 10.1093/cid/ciaa344.
31. Bénézit F, Le Turnier P, Declerck C et al. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. *Lancet Infect Dis*. 2020 doi: 10.1016/S1473-3099(20)30297-8



## Tables and Figures

**Table 1. Sociodemographic characteristics of the 1340 participants of the SARS-CoV-2, France from 28-30 April 2020**

**Table 2. Infection attack rate (IAR) according to sociodemographic characteristics**

**Table 3. IAR (%) by symptoms and type of participant**

**Figure 1. Flowchart of enrolment of participants**

**Figure 2. Timeline of symptom onset among (A) 107 symptomatic individuals who were seropositive for anti-SARS-CoV-2 antibodies; (B) 631 symptomatic individuals who were seronegative for anti-SARS-CoV-2 antibodies.**

**Figure S1. Infection attack rate (IAR) (%) among types of participants**

**Table 1. Sociodemographic characteristics of the 1340 participants of the SARS-CoV-2, France, 28-30 April 2020**

	Teaching staff (n=42)	Non-teaching staff (n=28)	Pupils (n=510)	Parents (n=641)	Relatives (n=119)	Total (n=1340)
<b>Male gender</b>	4 (9.5)	3 (10.7)	259 (50.8)	252 (39.3)	53 (44.5)	571 (42.6)
<b>Age (in years)</b>						
≤ 7	0 (0)	0 (0)	152 (29.8)	0 (0)	9 (7.6)	161 (12.0)
8-9	0 (0)	0 (0)	203 (39.8)	0 (0)	2 (1.7)	205 (15.3)
10-11	0 (0)	0 (0)	155 (30.4)	0 (0)	18 (15.1)	173 (12.9)
12-17	0 (0)	0 (0)	0 (0)	0 (0)	78 (65.6)	78 (5.8)
18-44	19 (45.2)	12 (42.9)	0 (0)	501 (78.2)	10 (8.4)	542 (40.5)
45-64	23 (54.8)	16 (57.1)	0 (0)	138 (21.5)	2 (1.7)	179 (13.4)
≥ 65	0 (0)	0 (0)	0 (0)	2 (0.3)	0 (0)	2 (0.1)
<b>School</b>						
A	5 (11.9)	10 (35.7)	61 (12.0)	67 (10.4)	20 (16.8)	163 (12.2)
B	5 (11.9)	7 (25.0)	90 (17.6)	108 (16.8)	18 (15.1)	228 (17.0)
C	6 (14.3)	4 (14.3)	68 (13.3)	78 (12.2)	15 (12.6)	171 (12.8)
D	8 (19.0)	4 (14.3)	87 (17.1)	116 (18.1)	24 (20.2)	239 (17.8)
E	11 (26.2)	0 (0.0)	117 (22.9)	151 (23.6)	25 (21.0)	304 (22.7)
F	7 (16.7)	3 (10.7)	87 (17.1)	121 (18.9)	17 (14.3)	235 (17.5)

Table 2. Infection attack rate (IAR) according to sociodemographic characteristics

	N	n (%)	P value
<b>Gender</b>			
Male	571	54 (9.5)	0.34
Female	769	85 (11.1)	
<b>Age (in years)</b>			
≤ 7	161	10 (6.2)	0.36
8-9	205	20 (9.8)	
10-11	173	16 (9.2)	
12-17	78	12 (15.4)	
18-44	542	62 (11.4)	
45-64	179	19 (10.6)	
≥ 65	2	0 (0.0)	
<b>Type of participant</b>			
Pupil	510	45 (8.8)	0.29
Teacher	42	3 (7.1)	
Non-teaching staff	28	1 (3.6)	
All parents	641	76 (11.9)	
Parent of an infected pupil	59	36 (61.0)	
Parent of a non-infected pupil	582	40 (6.9)	
All relatives living in the same household	119	14 (11.8)	
Relatives of an infected pupil	9	4 (44.4)	
Relatives of a non-infected pupil	110	10 (9.1)	

Table 3. IAR (%) by symptoms and type of participant

Symptoms	Children			Adults			Total		
	N	n (%)	P value	N	n (%)	P value	N	n (%)	P value
<b>Fever</b>									
Yes	136	16 (11.8)	0.29	152	35 (23.0)	<0.001	288	51 (17.7)	<0.001
No	481	42 (8.7)		571	46 (8.1)		1052	88 (8.4)	
<b>Cough</b>									
Yes	145	12 (8.3)	0.60	202	39 (19.3)	<0.001	347	51 (14.7)	0.002
No	472	46 (9.7)		521	42 (8.1)		993	88 (8.9)	
<b>Dyspnea</b>									
Yes	30	5 (16.7)	0.16	90	22 (24.4)	<0.001	120	27 (22.5)	<0.001
No	587	53 (9.0)		633	59 (9.3)		1220	112 (9.2)	
<b>Ageusia</b>									
Yes	7	2 (28.6)	0.13	52	39 (75.0)	<0.001	59	41 (69.5)	<0.001
No	610	56 (9.2)		671	42 (6.3)		1281	98 (7.6)	
<b>Anosmia</b>									
Yes	6	2 (33.3)	0.10	43	39 (90.7)	<0.001	49	41 (83.7)	<0.001

	No	611	56 (9.2)		680	42 (6.2)		1291	98 (7.6)	
<b>Muscle pain</b>										
	Yes	50	5 (10.0)	0.88	157	36 (22.9)	<0.001	207	41 (19.8)	<0.001
	No	567	53 (9.3)		566	45 (7.9)		1133	98 (8.7)	
<b>Sore throat</b>										
	Yes	108	11 (10.2)	0.76	154	24 (15.6)	0.05	262	35 (13.4)	0.08
	No	509	47 (9.2)		569	57 (10.0)		1078	104 (9.6)	
<b>Rhinorrhea</b>										
	Yes	111	13 (11.7)	0.36	142	21 (14.8)	0.13	253	34 (13.4)	0.08
	No	506	45 (8.9)		581	60 (10.3)		1087	105 (9.7)	
<b>Headache</b>										
	Yes	118	11 (9.3)	0.97	203	39 (19.2)	<0.001	321	50 (15.6)	<0.001
	No	499	47 (9.4)		520	42 (8.1)		1019	89 (8.7)	
<b>Fatigue</b>										
	Yes	97	15 (15.5)	0.03	220	48 (21.8)	<0.001	317	63 (19.9)	<0.001
	No	520	43 (8.3)		503	33 (6.6)		1023	76 (7.4)	
<b>Chest pain</b>										

	Yes	0	0 (0.0)	-	6	0 (0.0)	0.99	6	0 (0.0)	0.99
	No	617	58 (9.4)		717	81 (11.3)		1334	139 (10.4)	
<b>Nausea</b>										
	Yes	3	1 (33.3)	0.26	9	3 (33.3)	0.07	12	4 (33.3)	0.01
	No	614	57 (9.3)		714	78 (10.9)		1328	135 (10.2)	
<b>Vomiting</b>										
	Yes	27	2 (7.4)	0.99	17	2 (11.8)	0.99	44	4 (9.1)	0.78
	No	590	56 (9.5)		706	79 (11.2)		1296	135 (10.4)	
<b>Abdominal pain</b>										
	Yes	8	0 (0.0)	0.99	10	2 (20.0)	0.31	18	2 (11.1)	0.92
	No	609	58 (9.5)		713	79 (11.1)		1322	137 (10.4)	
<b>Diarrhea</b>										
	Yes	53	10 (18.9)	0.01	93	16 (17.2)	0.05	146	26 (17.8)	0.002
	No	564	48 (8.5)		630	65 (10.3)		1194	113 (9.5)	
<b>Symptom severity</b>										
	None	307	24 (7.8)		295	8 (2.7)		602	32 (5.3)	
	Minor only	97	9 (9.3)	0.32	129	7 (5.4)	<0.001	226	16 (7.1)	<0.001

Major	213	25 (11.7)		299	66 (22.1)		512	91 (17.8)	
<b>Medical consultation*</b>									
Yes	110	9 (8.2)	0.24	155	30 (19.3)	0.36	265	39 (14.7)	0.93
No	199	25 (12.6)		271	43 (15.9)		470	68 (14.5)	
<b>Hospitalization</b>									
Yes	3	0 (0.0)	0.56	6	2 (33.3)	0.08	9	2 (22.2)	0.24
No	614	58 (9.5)		717	79 (11.0)		1331	137 (10.3)	

\* Only among participants who declared symptoms




Figure 1. Flowchart of enrolment of participants







Figure 2. Timeline of symptom onset among (A) 107 symptomatic individuals who were seropositive for anti-SARS-CoV-2 antibodies; (B) 631 symptomatic individuals who were seronegative for anti-SARS-CoV-2 antibodies.

**SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission**

**Supplementary Material**

Supplementary Material Table S1. Symptoms by adult/child category

	Children (n = 617)	Adults (n = 723)	Total (n = 1340)
Fever	136 (22.0)	152 (21.0)	288 (21.5)
Cough	145 (23.5)	202 (27.9)	347 (25.9)
Dyspnea	30 (4.9)	90 (12.4)	120 (9.0)
Ageusia	7 (1.1)	52 (7.2)	59 (4.4)
Anosmia	6 (1.0)	43 (5.9)	49 (3.7)
Muscle pain	50 (8.1)	157 (21.7)	207 (15.4)
Sore throat	108 (17.5)	154 (21.3)	262 (19.5)
Rhinorrhea	111 (18.0)	142 (19.6)	253 (18.9)
Headache	118 (19.1)	203 (28.1)	321 (24.0)
Fatigue	97 (15.7)	220 (30.4)	317 (23.7)
Chest pain	0 (0.0)	6 (0.8)	6 (0.4)
Nausea	3 (0.5)	9 (1.2)	12 (0.9)
Vomiting	27 (4.4)	17 (2.4)	44 (3.3)
Abdominal pain	8 (1.3)	10 (1.4)	18 (1.3)
Diarrhea	53 (8.6)	93 (12.9)	146 (10.9)
Major symptoms	213 (34.5)	299 (41.4)	512 (38.2)
Minor symptoms	97 (15.7)	129 (17.8)	226 (16.9)
No symptoms reported	307 (49.8)	295 (40.8)	602 (44.9)
Medical consultation	116 (18.8)	160 (22.1)	276 (20.6)
Hospitalisation	3 (0.5)	6 (0.8)	9 (0.7)




Figure S1. Infection attack rate (IAR) (%) among types of participants